Efficacy and safety of the anti-interleukin-1 beta antibody canakinumab in patients with Schnitzler's syndrome

被引：0
|
作者：
de Koning, H. [1 ]
Schalkwijk, J. [1 ]
van der Ven-Jongekrijg, J. [1 ]
Stoffels, M. [1 ]
van der Meer, J. [1 ]
Simon, A. [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
来源：
ALLERGY | 2012年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
234
引用
收藏
页码：106 / 106
页数：1
相关论文
共 50 条
  • [1] EFFICACY, SAFETY AND PHARMACOKINETICS OF THE ANTI-INTERLEUKIN-1 BETA ANTIBODY CANAKINUMAB IN PATIENTS WITH SCHNITZLER SYNDROME
    De Koning, H. D.
    Schalkwijk, J.
    van der Ven-Jongekrijg, J.
    Stoffels, M.
    van der Meer, J. W.
    Simon, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 283 - 283
  • [2] Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome
    de Koning, Heleen D.
    Schalkwijk, Joost
    van der Ven-Jongekrijg, Johanna
    Stoffels, Monique
    van der Meer, Jos W. M.
    Simon, Anna
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) : 1634 - 1638
  • [3] Interleukin-1 Beta It Is: High Efficacy of Canakinumab In Schnitzler Syndrome.
    de Koning, Heleen D.
    Schalkwijk, Joost
    van der Ven-Jongekrijg, Johanna
    Stoffels, Monique
    van der Meer, Jos W. M.
    Simon, Anna
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S952 - S953
  • [4] In vivo and ex vivo suppression of inflammation during anti-interleukin-1 beta treatment in Schnitzler's syndrome
    de Koning, H. D.
    Schalkwijk, J.
    van der Ven-Jongekrijg, J.
    van Vlijmen-Willems, I. M.
    Rodijk-Olthuis, D.
    Stoffels, M.
    van der Meer, J. W.
    Simon, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S22 - S22
  • [5] Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
    Abhijit Chakraborty
    Stacey Tannenbaum
    Christiane Rordorf
    Philip J. Lowe
    David Floch
    Hermann Gram
    Sandip Roy
    Clinical Pharmacokinetics, 2012, 51 (6) : e1 - e18
  • [6] EFFICACY AND SAFETY PROFILE OF ANTI-INTERLEUKIN-1 TREATMENT IN BEHCET'S DISEASE
    Cantarini, L.
    Emmi, G.
    Talarico, S.
    Lopalco, G.
    Cimaz, R.
    Cantini, F.
    Viapiana, O.
    Olivieri, I
    Goldoni, M.
    Vitale, A.
    Silvestri, E.
    Prisco, D.
    Lapadula, G.
    Iannone, F.
    Galeazzi, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : S149 - S149
  • [7] Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review
    Betrains, A.
    Staels, F.
    Vanderschueren, S.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (04) : 636 - 642
  • [8] Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study
    Emmi, Giacomo
    Talarico, Rosaria
    Lopalco, Giuseppe
    Cimaz, Rolando
    Cantini, Fabrizio
    Viapiana, Ombretta
    Olivieri, Ignazio
    Goldoni, Matteo
    Vitale, Antonio
    Silvestri, Elena
    Prisco, Domenico
    Lapadula, Giovanni
    Galeazzi, Mauro
    Iannone, Florenzo
    Cantarini, Luca
    CLINICAL RHEUMATOLOGY, 2016, 35 (05) : 1281 - 1286
  • [9] First Reported Cases Of Schnitzler Syndrome Successfully Treated With Canakinumab (anti-IL-1-beta)
    Fox, R.
    Pesek, R. D.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB227 - AB227
  • [10] Efficacy and Safety of Canakinumab (ACZ885), a Fully Human Anti-Interleukin-1β-Antibody, in Cryopyrin Associated Periodic Fever Syndrome Results of a Multicenter, Randomized, Double-blind, Phase III Study
    Lachman, H.
    Kone-Paut, I.
    Kuemmerle-Deschner, J.
    Leslie, K.
    Hachulla, E.
    Quartier, P.
    Gitton, X.
    Patel, N.
    Lheritier, K.
    Hawkins, P. N.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (03) : 732 - 732
12345